Compugen Reports Fourth Quarter and Full Year 2024 Results

Provided By PR Newswire

Last update: Mar 4, 2025

HOLON, Israel, March 4, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today reported financial results for the fourth quarter and full year 2024 and provided a corporate update.